NDC 50102-100

LYZA

Norethindrone

LYZA is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Afaxys Pharma Llc. The primary component is Norethindrone.

Product ID50102-100_230b1884-dd75-444c-a430-624a863a5195
NDC50102-100
Product TypeHuman Prescription Drug
Proprietary NameLYZA
Generic NameNorethindrone
Dosage FormTablet
Route of AdministrationORAL
Marketing Start Date2013-06-24
Marketing CategoryANDA / ANDA
Application NumberANDA200980
Labeler NameAfaxys Pharma LLC
Substance NameNORETHINDRONE
Active Ingredient Strength0 mg/1
Pharm ClassesProgesterone Congeners [CS],Progestin [EPC]
NDC Exclude FlagE
Listing Certified Through2018-12-31

Packaging

NDC 50102-100-03

3 PACKAGE in 1 CARTON (50102-100-03) > 1 BLISTER PACK in 1 PACKAGE (50102-100-10) > 28 TABLET in 1 BLISTER PACK (50102-100-00)
Marketing Start Date2017-07-01
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 50102-100-47 [50102010047]

LYZA TABLET
Marketing CategoryANDA
Application NumberANDA200980
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2013-06-24
Marketing End Date2013-07-17

NDC 50102-100-00 [50102010000]

LYZA TABLET
Marketing CategoryANDA
Application NumberANDA200980
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2013-07-17

NDC 50102-100-01 [50102010001]

LYZA TABLET
Marketing CategoryANDA
Application NumberANDA200980
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2013-07-17

NDC 50102-100-10 [50102010010]

LYZA TABLET
Marketing CategoryANDA
Application NumberANDA200980
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2017-06-16

NDC 50102-100-03 [50102010003]

LYZA TABLET
Marketing CategoryANDA
Application NumberANDA200980
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2017-07-01

NDC 50102-100-48 [50102010048]

LYZA TABLET
Marketing CategoryANDA
Application NumberANDA200980
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2013-07-18

Drug Details

Active Ingredients

IngredientStrength
NORETHINDRONE.35 mg/1

OpenFDA Data

SPL SET ID:fe2cb3eb-dcd0-470c-8cf0-78fda554b1f7
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 1430383
  • 198042
  • 748961
  • Pharmacological Class

    • Progesterone Congeners [CS]
    • Progestin [EPC]

    Medicade Reported Pricing

    50102010048 LYZA 0.35 MG TABLET

    Pricing Unit: EA | Drug Type:

    50102010010 LYZA 0.35 MG TABLET

    Pricing Unit: EA | Drug Type:

    50102010003 LYZA 0.35 MG TABLET

    Pricing Unit: EA | Drug Type:

    50102010001 LYZA 0.35 MG TABLET

    Pricing Unit: EA | Drug Type:

    NDC Crossover Matching brand name "LYZA" or generic name "Norethindrone"

    NDCBrand NameGeneric Name
    50102-100LYZAnorethindrone
    53002-1687LYZAnorethindrone
    51862-102CamilaNorethindrone
    51862-884CAMILANORETHINDRONE
    16714-440DEBLITANENorethindrone
    0555-0344ErrinNorethindrone
    51862-100ErrinNorethindrone
    51862-886ERRINNORETHINDRONE
    57297-877Jencyclanorethindrone
    52544-892JolivetteNORETHINDRONE
    50102-300LyleqNORETHINDRONE
    53002-1793LyleqNORETHINDRONE
    52544-629Nora BENorethindrone
    0378-7272NorethindroneNorethindrone
    0378-7292NORETHINDRONEnorethindrone
    50090-2150NorethindroneNorethindrone
    50090-6161NORETHINDRONENORETHINDRONE
    57297-876NORETHINDRONENORETHINDRONE
    63187-748NorethindroneNorethindrone
    42291-650Norethindrone AcetateNorethindrone
    50268-602Norethindrone AcetateNorethindrone
    50090-3235Norlydanorethindrone
    51660-127NORLYROCnorethindrone
    50458-194Ortho MicronorNORETHINDRONE
    16714-441SHAROBELNorethindrone
    50102-200TulanaNORETHINDRONE
    53002-2687TulanaNORETHINDRONE

    Trademark Results [LYZA]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    LYZA
    LYZA
    85879467 4523185 Live/Registered
    Afaxys, Inc.
    2013-03-18
    LYZA
    LYZA
    77674711 not registered Dead/Abandoned
    Afaxys, Inc.
    2009-02-20
    LYZA
    LYZA
    77296222 3644281 Dead/Cancelled
    EYERIS, INC.
    2007-10-04

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.